TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7974935

Group type: EXPERIMENTAL
Intervention: 15 mg/day propiverine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 30 mg/day propiverine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 45 mg/day propiverine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 60 mg/day propiverine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Propiverine (doses of 15, 30, 45 and 60 mg/day)
Number of subjects: 66
Study: 2647494

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin plus dipyridamole
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Triflusal plus dipyridamole
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo plus dipyridamole
Number of subjects: 209
Study: 4908342

Group type: EXPERIMENTAL
Intervention: 1-adamantanamine hydrochloride (aminoadamantane) 100 mg every 12 hours for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31200641

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus (PIB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 42
Study: 28477414

Group type: EXPERIMENTAL
Intervention: Basal insulin therapy
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Biphasic insulin therapy
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Prandial insulin therapy
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Glycated albumin
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 625
Study: 25200448

Group type: EXPERIMENTAL
Intervention: Listening to music for 10 min
Number of subjects: 92

Group type: COMPARATOR
Intervention: Waiting in silence
Number of subjects: 92
Study: 23648946

Group type: EXPERIMENTAL
Intervention: Ambrisentan, 10 mg/d
Number of subjects: 492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study: 21314920

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Talking Control (TC)
Number of subjects: 204
Study: 19826286

Group type: EXPERIMENTAL
Intervention: Low-load resistance training with slow movement and tonic force generation (LST) at approximately 60% 1RM, 3-second lifting, and 3-second lowering, performed twice a week for 13 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-intensity exercise at normal speed (HM) at 85% 1RM, 1-second lifting, 1-second lowering, and 1-second relaxed movement, performed twice a week for 13 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary control (CON) group
Number of subjects: 24
Study: 16566418

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15356664

Group type: EXPERIMENTAL
Intervention: Home-centered monitoring through telemedicine (measuring blood pressure and body weight three times a week for 6 months)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Home-centered monitoring through telemedicine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 122
Study: 11579330

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of morphine following induction and placebo saline during peritoneal closure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo saline following induction and 0.15 mg/kg of morphine during peritoneal closure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo saline both during induction and peritoneal closure
Number of subjects: 60
Study: 9685791

Group type: EXPERIMENTAL
Intervention: Conventional trabeculectomy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with sutures
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sutureless phacoemulsification
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 141
Study: 8304366

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 3289113

Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29599067

Group type: EXPERIMENTAL
Intervention: Primary Bypass (PB)
Number of subjects: 239
Study: 28822510

Group type: EXPERIMENTAL
Intervention: 80-mg atorvastatin
Number of subjects: 1027

Group type: COMPARATOR
Intervention: 10-mg atorvastatin
Number of subjects: 1027
Study: 26296862

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol administered via dry powder inhalers
Number of subjects: 60
Study: 22680300

Group type: EXPERIMENTAL
Intervention: Protocol 1: 90% anorganic bovine bone + 10% porcine collagen fibers + resorbable bilayer membrane (non-cross-linked porcine types I and III collagen)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Protocol 2: 70% cross-linked type I bovine collagen sponge + non-sintered hydroxyapatite + resorbable membrane (type I porcine collagen cross-linked by natural ribose glycation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of both protocols
Number of subjects: 44
Study: 21604899

Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Overly Nurturant subtype)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Intrusive subtype)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Socially Avoidant subtype)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Short-term treatment for GAD patients (Nonassertive subtype)
Number of subjects: 52
Study: 18426626

Group type: EXPERIMENTAL
Intervention: FM-TCI
Number of subjects: 56

Group type: COMPARATOR
Intervention: MCI-controlled
Number of subjects: 56
Study: 12625833

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEE; 0.625 mg/day; n = 14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Raloxifene (150 mg/day; n = 13)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 40
Study: 10658376

Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuit
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonheparin-bonded control circuit
Number of subjects: 24
Study: 8557867

Group type: EXPERIMENTAL
Intervention: 0.25 g nitrogen (N)/kg Ideal Body Weight (IBW)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 0.12 g nitrogen (N)/kg Ideal Body Weight (IBW)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 0.18 g nitrogen (N)/kg Ideal Body Weight (IBW)
Number of subjects: 35
Study: 2128866

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Colestyramine 16 g
Number of subjects: 55
Study: 488523

Group type: EXPERIMENTAL
Intervention: sulphinpyrazone (600‐800 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study: 30680870

Group type: EXPERIMENTAL
Intervention: Parent programme (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Care as usual (n = 30)
Number of subjects: 60
Study: 28161147

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg/0.05 ml)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Pattern scan PRP
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Conventional single-spot PRP
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: High-risk PDR or worse
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Moderate PDR or better
Number of subjects: 305
Study: 25860005

Group type: EXPERIMENTAL
Intervention: Bicyclol 75 mg/day (25 mg three times daily) in conjunction with glucurolactone 600 mg/day (200 mg three times daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group receiving glucurolactone 600 mg/day (200 mg three times daily) only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study: 23712523

Group type: EXPERIMENTAL
Intervention: Self-sampling kit for HPV testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second invitation for a free Pap-smear
Number of subjects: 0
Study: 22313831

Group type: EXPERIMENTAL
Intervention: Allogeneic block grafts impregnated with autologous bone marrow
Number of subjects: 10

Group type: COMPARATOR
Intervention: Allogeneic block grafts (control group)
Number of subjects: 10
Study: 19576349

Group type: EXPERIMENTAL
Intervention: Primary angioplasty with stent implantation
Number of subjects: 1572

Group type: COMPARATOR
Intervention: In-hospital fibrinolysis with alteplase
Number of subjects: 1572
Study: 17241493

Group type: EXPERIMENTAL
Intervention: Relational Psychotherapy Mothers' Group (RPMG)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Recovery Training (RT)
Number of subjects: 127
Study: 15789978

Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees toothbrush
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral‐B Indicator toothbrush
Number of subjects: 31

Group type: COMPARATOR
Intervention: Crest SpinBrush PRO toothbrush
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 31
Study: 11748775

Group type: EXPERIMENTAL
Intervention: haloperidol (0.5 to 2 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: risperidone (0.5 to 2 mg/day)
Number of subjects: 58
Study: 9597563

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine suppositories (MSC-R)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Controlled-release morphine tablets (MSC-T)
Number of subjects: 27
Study: 8044919

Group type: EXPERIMENTAL
Intervention: Aggressive lipoprotein manipulation
Number of subjects: 2095
Study: 29705451

Group type: EXPERIMENTAL
Intervention: Barberry juice (BJ), 200 ml daily for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 28006831

Group type: EXPERIMENTAL
Intervention: Desmopressin melt (lyophilisate)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Desmopressin tablets
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both treatments (melt and tablets)
Number of subjects: 134
Study: 26037429

Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS) containing 47 mg of potassium iodate and 3300 mg of microencapsulated ferrous fumarate (1100 mg elemental iron) per kg of salt
Number of subjects: 245

Group type: COMPARATOR
Intervention: Iodized salt (control group)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS)
Number of subjects: 245
Study: 22540849

Group type: EXPERIMENTAL
Intervention: Equipercentile equating method
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Linear equating method
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Raw AVLT scores
Number of subjects: 2200
Study: 20163984

Group type: EXPERIMENTAL
Intervention: Automatic slow eye movement (SEM) analysis during the multiple sleep latency test (MSLT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Automatic slow eye movement (SEM) analysis during the maintenance of wakefulness test (MWT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of SEM latency with sleep latency at MSLT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of SEM latency with sleep latency at MWT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of Epworth Sleepiness Scale score with SEM latency at MWT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of Epworth Sleepiness Scale score with SEM latency at MSLT
Number of subjects: 20
Study: 19635340

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises and urge suppression techniques
Number of subjects: 0
Study: 16788299

Group type: EXPERIMENTAL
Intervention: Regular dose ASA+MR-DP (b.i.d. on days 5-28)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Reduced dose ASA+MR-DP (once daily before bed during days 5-14, b.i.d. on days 15-28)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (days 1-28)
Number of subjects: 146
Study: 15299060

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administered intravenously at a dosage of 1 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous-infusion H(2)(15)O PET
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of CBF
Number of subjects: 10
Study: 10665516

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dorzolamide 2.0% t.i.d.
Number of subjects: 0
Study: 9354317

Group type: EXPERIMENTAL
Intervention: Tedisamil (100 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Tedisamil and Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tedisamil alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tedisamil alone and in combination with Atenolol
Number of subjects: 0
Study: 8308936

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg t.i.d.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo 10 mg t.i.d.
Number of subjects: 56
Study: 2952125

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31620778

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905
Study: 29725790

Group type: EXPERIMENTAL
Intervention: Active, Linkage, Engagement, Retention and Treatment (ALERT) specialist for outreach and health coaching
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 116
Study: 26365587

Group type: EXPERIMENTAL
Intervention: 4% citrate anticoagulation
Number of subjects: 37

Group type: COMPARATOR
Intervention: 15% citrate anticoagulation
Number of subjects: 37
Study: 24781720

Group type: EXPERIMENTAL
Intervention: Recumbent cycling exercise during dialysis
Number of subjects: 65

Group type: COMPARATOR
Intervention: Simple stretching exercises (Control)
Number of subjects: 65
Study: 22947269

Group type: EXPERIMENTAL
Intervention: Standard treatment supported by self‐monitoring (pro‐active counseling, pedometer, weighing scale, blood pressure device)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard treatment without self‐monitoring
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Standard treatment supported by self‐monitoring
Number of subjects: 179
Study: 20369524

Group type: EXPERIMENTAL
Intervention: High-flex prosthesis (HF group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional posterior-stabilized prosthesis (PS group)
Number of subjects: 58
Study: 18302810

Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15546895

Group type: EXPERIMENTAL
Intervention: Direct access group
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study: 12463319

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study: 10348579

Group type: EXPERIMENTAL
Intervention: Adjunctive abciximab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 20
Study: 7569458

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg od plus amoxicillin 500 mg tid (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 260 mg bid, metronidazole 250 mg tid and amoxicillin 500 mg tid (group B)
Number of subjects: 80
Study: 1943411

Group type: EXPERIMENTAL
Intervention: Hypercaloric parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypocaloric parenteral nutrition
Number of subjects: 0
Study: 7026255

Group type: EXPERIMENTAL
Intervention: Captopril (1 mg/kg body weight)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 12
Study: 31196765

Group type: EXPERIMENTAL
Intervention: TR‐RPDs
Number of subjects: 28
Study: 30664267

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF), 12 doses of 300 μg each in 28 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 33
Study: 28508697

Group type: EXPERIMENTAL
Intervention: Topical estrogen (GI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical genistein (GII)
Number of subjects: 30
Study: 26422051

Group type: EXPERIMENTAL
Intervention: Exercise intervention (300 min/week at lactate threshold)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (maintain usual lifestyle)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 81
Study: 24139829

Group type: EXPERIMENTAL
Intervention: Subcutaneous allergen immunotherapy (SCIT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (SLIT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22080312

Group type: EXPERIMENTAL
Intervention: Bodypump® training (n = 9)
Number of subjects: 19
Study: 19121220

Group type: EXPERIMENTAL
Intervention: Low intensity self-management lifestyle intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard education (control)
Number of subjects: 250
Study: 17537205

Group type: EXPERIMENTAL
Intervention: 8-mm gold tip catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Externally irrigated-tip catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8-mm platinum-iridium tip catheter
Number of subjects: 60
Study: 15072897

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study: 11287024

Group type: EXPERIMENTAL
Intervention: Paracervical block with conscious sedation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Paracervical block only (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Paracervical block with and without conscious sedation
Number of subjects: 150
Study: 9250791

Group type: EXPERIMENTAL
Intervention: Prophylaxis for opportunistic infections including immunoglobulin (3.5 months), pyrimethamine-sulfadiazine (4 months), fluconazole (2.5 months), cotrimoxazole or pentamidine (2 years), penicillin (lifelong), and dietary precautions (4 months).
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Prophylaxis for opportunistic infections developed on an ongoing basis as new infectious complications were seen.
Number of subjects: 7
Study: 8510706

Group type: EXPERIMENTAL
Intervention: Diazepam (0.33 mg/kg) administered orally every eight hours during febrile illnesses
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo administered orally every eight hours during febrile illnesses
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Diazepam (in children who had seizures while receiving the medication)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Diazepam (among children who took at least one dose)
Number of subjects: 406
Study: 3499163

Group type: EXPERIMENTAL
Intervention: Fasted overnight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postprandial
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasting and 15 ml aluminium hydroxide gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postprandial and 15 ml aluminium hydroxide gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasting and 15 ml aluminium and magnesium hydroxide gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postprandial and 15 ml aluminium and magnesium hydroxide gel
Number of subjects: 12
Study: 31446143

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 28342633

Group type: EXPERIMENTAL
Intervention: PCA3 test (PCA3 ≥35)
Number of subjects: 5199

Group type: COMPARATOR
Intervention: Observation (PCA3 <35)
Number of subjects: 5199

Group type: COMPARATOR
Intervention: ERSPC RC‐3
Number of subjects: 5199

Group type: EXPERIMENTAL
Intervention: PCA3-35 to avoid IBx
Number of subjects: 5199
Study: 26289996

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23374879

Group type: EXPERIMENTAL
Intervention: Physical exercise without a clear treatment rationale
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Physical exercise with treatment rationale
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Behavioural activation with treatment rationale
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Behavioural activation without a clear treatment rationale
Number of subjects: 500

Group type: COMPARATOR
Intervention: Waiting list control group with delayed treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: All treatment groups (including relapse prevention program)
Number of subjects: 500
Study: 20602868

Group type: EXPERIMENTAL
Intervention: Universal free healthy breakfast provision in intervention schools
Number of subjects: 4472
Study: 19325484

Group type: EXPERIMENTAL
Intervention: Early antifungal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study: 17543895

Group type: EXPERIMENTAL
Intervention: Chronic methylphenidate (MPH) 0.3 mg/kg/dose
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chronic methylphenidate (MPH) 0.6 mg/kg/dose
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15547635

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Epoetin alfa with exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Epoetin alfa without exercise
Number of subjects: 21